2017—2020年中国科学技术大学附属第一医院新型抗肿瘤药使用情况分析

Analysis of Use of New Anti-Tumor Drugs in the First Affiliated Hospital of University of Science and Technology of China from 2017 to 2020

目的:了解中国科学技术大学附属第一医院(以下简称"我院")新型抗肿瘤药的临床使用情况,为合理用药提供参考。方法:采用回顾性的方法,对2017—2020年我院新型抗肿瘤药的销售金额、用药频度(defined daily dose system,DDDs)、限定日费用(defined daily cost,DDC)及药品销售金额排序(B)/DDDs排序(A)进行统计分析。结果:2017—2020年,我院新型抗肿瘤药的销售金额呈现出波动的态势,从2017年的7696.00万元减少至2018年的6536.05万元,减少了15.07%;2019年增长至8588.94万元,较2018年增长了31.41%;2020年又减少至4426.18万元,较2019年减少了48.47%。然而,新型抗肿瘤药的品种数则逐年递增,从2017年的21个增长至2020年的53个。2017—2020年,伊马替尼的销售金额排序、DDDs排序均居第1位;2017—2019年,尼洛替尼、利妥昔单抗和硼替佐米的销售金额排序均居前5位;2017—2020年,吉非替尼、达沙替尼及埃克替尼的B/A>1,提示其价格低,使用频率高;大部分药品的DDC相对稳定,B/A接近于1,提示其销售金额与DDDs的同步性总体较好。结论:我院新型抗肿瘤药的临床使用相对合理,药品价格、上市时间及临床适应证对该类药品的使用影响较大。

OBJECTIVE:To probe into the clinical use of new anti-tumor drugs in the First Affiliated Hospital of University of Science and Technology of China(hereinafter referred to as"our hospital"),so as to provide reference for rational drug use.METHODS:Retrospective analysis was adopted,the consumption sum,defined daily dose system(DDDs),defined daily cost(DDC)and consumption sum ranking(B)/DDDs ranking(A)of new anti-tumor drugs in our hospital from 2017 to 2020 were analyzed statistically.RESULTS:From 2017 to 2020,the consumption sum of new anti-tumor drugs in our hospital showed the trend of fluctuation,decreased from 76960000 yuan in 2017 to 65360500 yuan in 2018,with the decrease of 15.07%.In 2019,the consumption sum increased to 85889400 yuan,with the increase of 31.41%over 2018.In 2020,the consumption sum decreased to 44261800 yuan,with the decrease of 48.47%over 2019.However,the number of new anti-tumor drugs increased year by year,from 21 in 2017 to 53 in 2020.From 2017 to 2020,imatinib took the lead in terms of consumption sum and DDDs.From 2017 to 2019,the consumption sum of nilotinib,rituximab and bortezomib ranked the top 5.From 2017 to 2020,the B/A of gefitinib,dasatinib and ectinib was higher than 1,suggesting lower price and higher frequency of use.The DDC of most drugs was relatively stable,with B/A close to 1,indicating that the consumption sum was in good synchronization with DDDs.CONCLUSIONS:The clinical use of new anti-tumor drugs in our hospital is relatively reasonable,and drug price,marketing time and clinical indications have greater influence on the use of these drugs.